Literature DB >> 26886685

The Prevalence of Vitreomacular Interface Pathology in a Spanish Tertiary Hospital.

Ignacio Flores-Moreno1, Luis Arias-Barquet, María Vidal-Martí, Alex Muñoz-Blanco, Marcos J Rubio-Caso, José Maria Ruiz-Moreno, Jay S Duker, Josep M Caminal.   

Abstract

PURPOSE: To determine the prevalence of vitreomacular interface (VMI) pathology, using spectral-domain optical coherence tomography (SD-OCT).
METHODS: VMI status was classified into macular posterior vitreous detachment (PVD), focal vitreomacular adhesion (VMA; ≤1,500 μm), broad VMA (>1,500 μm), focal vitreomacular traction (VMT; ≤1,500 μm), broad VMT (>1,500 μm), full-thickness macular hole (FTMH) with the presence of VMT, and FTMH without the presence of VMT.
RESULTS: A total of 1,976 eyes were included. A nonpathologic VMI was observed in 1,875 eyes (94.8%), including 1,050 (53.1%) with PVD, 120 (6.1%) with focal VMA and 705 (35.6%) with broad VMA. A pathologic state of the VMI was diagnosed in 101 eyes (5.1%). Thirty-three eyes (1.7%) were classified as focal VMT, 29 (1.4%) as broad VMT, 39 (1.9%) as FTMH, resulting in 6 small, 12 medium and 21 large FTMHs, six eyes had VMT associated to FTMH.
CONCLUSIONS: Even in a tertiary care, retinal referral practice, VMI pathology is a relatively rare condition. There was a higher prevalence in a tertiary hospital study compared to population-based studies.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 26886685     DOI: 10.1159/000443937

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  2 in total

1.  Vitreomacular Interface Disorders in Proliferative Diabetic Retinopathy: An Optical Coherence Tomography Study.

Authors:  Aidi Lin; Honghe Xia; Anlin Zhang; Xinyu Liu; Haoyu Chen
Journal:  J Clin Med       Date:  2022-06-07       Impact factor: 4.964

2.  Qualitative and quantitative assessment of posterior segment optical coherence tomography images using standard photos: the Liwan Eye Study.

Authors:  Sean K Wang; Xinxing Guo; Ou Xiao; Yanxian Chen; Ran Liu; Wenyong Huang; Mingguang He
Journal:  BMJ Open       Date:  2017-12-22       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.